Geron Corporation
0IV3.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$820.91M
Close$
Share Statistics
| Market cap | $820.91 Million |
|---|---|
| Enterprise Value | $880.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 0.59 |
| Outstanding Shares | 670,696,000 |
Return
| Return on Equity | -31.97% |
|---|---|
| Return on Assets | -13.47% |
| Return on Invested Capital | -7.33% |
Valuation & Multiples
| P/E Ratio | -12.29 |
|---|---|
| PEG | -659.66 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.3 |
| Enterprise Value to EBIT | -26.76 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$55.30 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$60.70 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Geron Corp.
258 employees
CEO: John Scarlett Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients...